share_log

Alector Shares Are Trading Lower After the Company Released Its INVOKE-2 Phase 2 Trial Results That Failed to Meet Its Primary Endpoint. Also, Bank of America Downgraded the Stock From Neutral to Underperform.

Benzinga ·  Dec 4 11:44
Alector Shares Are Trading Lower After the Company Released Its INVOKE-2 Phase 2 Trial Results That Failed to Meet Its Primary Endpoint. Also, Bank of America Downgraded the Stock From Neutral to Underperform.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment